CLINICAL_TRIALS ClinicalTrials.gov record update

Phase Ib Study to Assess the Efficacy and Safety of Epcoritamab in Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder

This page presents selected fields from the linked source record. It does not add a medical interpretation.

Record identity and dates

Source: ClinicalTrials.gov
Source record ID: NCT06672705
Title field or adapter rule: protocolSection.identificationModule.officialTitle
Ingested At: 2026-04-25T22:27:26.451944+00:00
Published At: 2025-08-19T00:00:00+00:00
Record Updated At: 2025-08-19
Timestamp Basis: source retrieval time was not retained by the feed adapter
Date limitation: source retrieval time was not retained by the feed adapter

protocolSection.conditionsModule.conditions: ["Diffuse Large B-Cell Lymphoma Post-Transplant Lymphoproliferative Disorder", "EBV-Related Post-Transplant Lymphoproliferative Disorder", "Recurrent Monomorphic Post-Transplant Lymphoproliferative Disorder", "Recurrent Polymorphic Post-Transplant Lymphoproliferative Disorder", "Refractory Monomorphic Post-Transplant Lymphoproliferative Disorder", "Refractory Polymorphic Post-Transplant Lymphoproliferative Disorder"]
protocolSection.statusModule.lastUpdatePostDateStruct.date: "2025-08-19"
protocolSection.identificationModule.nctId: "NCT06672705"
protocolSection.identificationModule.officialTitle: "Phase Ib Study to Assess the Efficacy and Safety of Epcoritamab in Relapsed or Refractory Post-Transplant Lymphoproliferative Disorder"
protocolSection.statusModule.overallStatus: "RECRUITING"
protocolSection.designModule.phases: ["PHASE1"]
protocolSection.statusModule.resultsFirstPostDateStruct.date: ""

Intervention details are not present in the imported fields for this record. No drug-condition relationship is inferred from co-listing.

This index keeps the source fields it imported; it may not contain the complete original record. Verify wording and context in the linked source.